Treatment for Adenocarcinoma

Recruiting · 18+ · Male · Philadelphia, PA

This study is evaluating whether a new drug may help slow the growth of prostate cancer.

See full description

About the trial for Adenocarcinoma

Eligible Conditions
Adenocarcinoma, Prostate · Adenocarcinoma

Treatment Groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.


This trial is for male patients aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Patients with history of treated brain metastases are eligible if off systemic corticosteroids for at least 2 weeks.
≥ 18 years of age.
No prior therapy with PARP inhibitor therapy.
ECOG performance status of ≤ 2.
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 12 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 12 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 1 primary outcome and 5 secondary outcomes in patients with Adenocarcinoma. Measurement will happen over the course of 1 month.

Frequency and severity of adverse events (AEs)
Frequency and severity of adverse events (AEs), as assessed by CTCAE version 5.0, following the initiation of niraparib maintenance therapy
Proportion of patients achieving a ≥30% decline in PSA following the initiation of niraparib maintenance therapy
Proportion of patients achieving a ≥50% decline in PSA following the initiation of niraparib maintenance therapy
Assessment of the 6-month radiographic progression-free survival (rPFS) rate in patients with platinum-sensitive mCRPC harboring germline or somatic DNA repair defects as determined by Kaplan-Meier analysis.
Time to PSA progression
Time until the first PSA increase that is >25% (and an absolute increase of ≥ 2 ng/ml) from the nadir PSA value following the initiation of niraparib maintenance therapy
Overall survival (OS)
Time from start of study therapy to death due to any cause. Patients who are alive will be censored on the most recent date of patient contact

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are common treatments for adenocarcinoma?

The most effective treatment for adenocarcinoma is surgical resection, especially curative resection in patients with early-stage cancers. Radiation therapy is beneficial for locally advanced cancers and is recommended as first-line treatment for distant metastases; postoperative radiation therapy is often recommended as part of adjuvant treatment. Chemotherapy is used for advanced and unresectable cancers. In addition, there are several novel therapies in clinical trials to be evaluated for treatment of carcinoma.

Anonymous Patient Answer

What causes adenocarcinoma?

Adenocarcinoma are a group of malignant neoplasms characterized by the presence of glandular structure or a mucin production. Mucin, as it is produced by the malignant cells, contributes to the tumor's invasive behavior. It is therefore conceivable that the mucin production in these neoplasms could favor distant metastasis. Anyway, the study of its pathogenesis requires further investigations, since these observations are not totally understood.

Anonymous Patient Answer

What are the signs of adenocarcinoma?

Adenocarcinoma presents as a mass. Non-mass lesions often occur and can be asymptomatic. In the setting of a history of alcohol or smoking, or symptoms of gastrointestinal or chest pain, it is extremely important to have an colonoscopy when detecting adenocarcinoma. Adenocarcinoma in this setting is usually adenocarcinoma of the colon with a good prognosis. As with the other gastrointestinal malignancies, the use of PET/CT scanning has allowed earlier detection of metastases to regional lymph nodes, liver, lung, or brain. The addition of CT scanning to standard evaluation may alter management in up to 25 % of cases.

Anonymous Patient Answer

Can adenocarcinoma be cured?

Completely pure adenocarcinoma of the pancreas can be cured. When it coexists in an adenoma, cure is possible if adenocarcinoma has not expanded locally. If adenocarcinoma has expanded locally, recurrence is high.

Anonymous Patient Answer

How many people get adenocarcinoma a year in the United States?

Results from a recent paper was based on data collected by the National Cancer Institute in the USA, and reflects the current experience of clinicians and scientists in the US. However, the results and conclusions are applicable throughout the world. The National Cancer Institute estimates that in 2006 there are a total of 1,093,564 new cases, 2,064,664 deaths from the disease and more than 600,000 patients diagnosed with malignant tumors of the lung, breast and cervical/vaginal system.

Anonymous Patient Answer

What is adenocarcinoma?

Adenocarcinoma is a type of cancer that results when cells form in glandular or intestinal structures of the intestine. This cancer consists of cells that come from the lining of the digestive tract.\n

Anonymous Patient Answer

What is treatment?

Adjunct therapies can be a powerful adjuvant for surgery to improve patient survival. Treatment usually consists of concurrent or sequential chemotherapy and/or radiotherapy. Surgical staging is commonly used to help identify patients at risk for metastatic disease. The exact role of surgical staging and multimodal therapies are not well understood. The best treatment strategy for metastatic PSC remains unclear. A multi-modal therapy with surgery, radio-chemotherapy, and adjuvant chemotherapy is recommended. Surgery should be performed to maximize local tumor control and prevent recurrence. Surgery is not curative but is an important component of treatment. As of right now, there are no effective adjuvant treatments for surgically treated PSC patients.

Anonymous Patient Answer

Have there been other clinical trials involving treatment?

If the current clinical trials are not successful, new therapies may be developed in the future. The NCI has recently created a database of all recent clinical trials involving treatments for a variety of cancers. A clinical trial is in progress at the NCI Cancer Center. The NCI is also going to create a website to guide patients through treatments available for different types of cancer, such as small cell lung carcinoma.

Anonymous Patient Answer

How does treatment work?

The use of cetuximab and paclitaxel alone or paclitaxel plus carboplatin is not significantly different compared with paclitaxel plus docetaxel for patients with advanced esophageal cancer.

Anonymous Patient Answer

How quickly does adenocarcinoma spread?

These authors' data show that adenocarcinoma spreads quickly. This data has a strong implication on the timing of possible clinical trials for patients with adenocarcinoma. If clinical trials will be in the early stage, they may not provide the patients enough clinical benefit to improve survival. This research implies that clinical trials should be conducted at a later stage of adenocarcinoma progression to prevent wasting time on trials where benefit is marginal.

Anonymous Patient Answer

What are the chances of developing adenocarcinoma?

Women who had a first-degree first-degree relative with colorectal adenocarcinoma have lower risk of developing adenocarcinoma in another organ. This may suggest that colorectal cancer predisposes women to developing adenocarcinoma of another organ. Higher percentage of MSS tumors and younger age at diagnosis also had a shorter time to developing adenocarcinoma.

Anonymous Patient Answer

What are the common side effects of treatment?

The most common side effects of systemic chemotherapy among cancer patients receiving treatment in one of Denmark's outpatient clinics were diarrhea and nausea. Less frequent side effects were constipation and rash. All side effects were found to be more frequent in patients who received adjuvant chemotherapy than in treatment-naïve patients.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Adenocarcinoma by sharing your contact details with the study coordinator.